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Abstract 
Background: V is a potent, poly(ADP-ribose) polymerase (PARP) inhibitor that obstructs DNA damage 
repair. BRCA1/2 tumors are defective in homologous recombination, which leads to more error-prone 
mechanisms of DNA repair and increased sensitivity to PARP inhibition. V enhances the antitumor 
activity of alkylating agents such as TMZ in preclinical models. In addition, V+TMZ showed promising 
activity in a single-arm phase 2 study in pts with BRCA1/2 mutations. This phase 2 trial (NCT01506609) 
investigated the efficacy and tolerability of V+TMZ (or V+C/P) compared to Plc+C/P in pts with locally 
recurrent or metastatic breast cancer harboring a BRCA1 or BRCA2 mutation. Results from the primary 
analysis for the V+TMZ arm vs Plc+C/P are presented, and the V+C/P vs Plc+C/P results will be presented 
separately. 
Methods: Male and female pts aged ≥18 years with histologically confirmed locally recurrent or 
metastatic breast cancer were randomized 1:1:1 to: 1) V 40 mg BID D1–7 + TMZ 150–200 mg/m2 QD D1–
5, 28-D cycle; 2) V 120 mg BID D1–7 + C AUC 6, D3 and P 175 mg/m2, D3, 21-D cycle; 3) placebo BID D1–
7 + C/P. Key eligibility criteria included known deleterious BRCA1/2 mutation, ≤2 prior chemotherapies 
for metastatic disease, no prior platinum agent, and no CNS metastases. Randomization was stratified 
by hormone receptor status, prior cytotoxic therapy (yes vs no), and ECOG PS (0–1 vs 2). The primary 
endpoint was progression-free survival (PFS) per RECIST 1.1 by independent review. Overall survival 
(OS), objective response rate (ORR), and safety/tolerability were also evaluated. 
Results: A total of 290 pts (284 BRCA+ per central lab) were randomized (V+TMZ, n=94 [91 BRCA+]). 
Baseline demographics and disease characteristics were comparable among treatment arms; 41.3% of 
pts had triple-negative breast cancer (TNBC) and 31.7% had received >2 prior regimens. Median study 
drug exposure was 6 cycles for the V+TMZ arm and 10 cycles for the Plc+C/P arm. Median PFS, median 
OS (interim), and ORR for V+TMZ were inferior to Plc+C/P (PFS 7.4 vs 12.3 mo, OS 19.1 vs 25.0 mo, and 
ORR 28.6% vs 61.3%). In pts with TNBC, median PFS was 5.5 (3.1–8.5) mo; 8.4 (6.8–10.6) mo for pts with 
non-TNBC. Treatment-emergent adverse events (AEs) of interest occurring differentially with V+TMZ are 
shown in Table 1. Grade ≥3 AEs in ≥30% of pts in the V+TMZ arm were thrombocytopenia (48%) and 
neutropenia (37%). 
Conclusions: V+TMZ provided durable responses, with less neutropenia, alopecia, and neuropathy than 
Plc+C/P; however, PFS, OS, and ORR were inferior in the TMZ arm compared to C/P. 
  
 Treatment-Emergent AEs, 
n (%) 
V+TMZ, 
n=93 
Plc+C/P, 
n=96 
Neutropenia 46 (50) 71 (74) 
Alopecia 10 (11) 55 (57) 
Peripheral neuropathy 11 (12) 56 (58) 
Thrombocytopenia 73 (79) 67 (70) 
Nausea 70 (75) 56 (58) 
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